课题基金 / 基金详情

ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)

ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)
心房颤动心律管理随访(确认)
批准号:
6274020
负责人:
EDWARD L PRITCHETT
金额:
$2.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

EDWARD L PRITCHETT的其他基金

相似基金

相关文献

中文摘要
翻译
心房颤动是一种常见的心律失常, 房颤的患病率随着年龄的增长而增加。 的流行病学 在研究中,房颤的患病率为1%的受试者年龄 50 - 59岁,但在80 - 89岁时增加到9%。 的存在 心房纤颤显著增加中风的风险。幸运的是, 华法林抗凝治疗是有效的治疗中风风险。 除了增加中风的风险外, 纤维性颤动通常有心悸、呼吸困难、疲劳 和头晕;有些病人的症状是致残的。 已经开发了各种策略来治疗心房肌萎缩症患者, 纤维性颤动 使用I类或III类抗心律失常药物 恢复窦性心律,减少房性心律失常的发生 纤颤是主要的治疗方法。 虽然这一战略已被证明 有效降低心房肌症状性复发的频率, 纤颤,对抗纤颤药物安全性的担忧, 对替代战略的兴趣增加,包括更简单的战略 房颤期间控制心率(β 阻断剂、地高辛、维拉帕米或地尔硫卓)。 一些病人正在 用希氏束消融和植入永久性 起搏器,它消除了所有药物治疗的需要,除了 抗凝 目前,这些替代品对生存的影响 房颤患者的治疗策略很简单, 未知 AFFIRM试验的总体目标是确定 维持I类或III类窦性心律的策略 抗疟疾药物不同于简单地控制 死亡率方面。 在AFFIRM试验中,患者 随机分配到这两个竞争策略中的一个。 一旦 任务已经完成,调查人员有很大的自由来决定 具体使用哪些药物或器械。 该方案将招募5000名 患者主要结局变量是死亡率。 几乎一半的 患者已经被招募。
英文摘要
Atrial fibrillation is a common disorder of the heart rhythm, and the prevalence of atrial fibrillation increases with age. In epidemiologic studies, the prevalence of atrial fibrillation is 1% for subjects age 50-59 years, but it increases to 9% at ages 80-89 years. The presence of atrial fibrillation markedly increases the risk of stroke. Fortunately, anticoagulation with warfarin is effective treatment for the stroke risk. In addition to the increased risk of stroke, patients with atrial fibrillation are often symptomatic with palpitations, dyspnea, fatigue, and dizziness; and symptoms are disabling in some patients. A variety of strategies have been developed to treat patients with atrial fibrillation. The use of Class I or Class III antiarrhythmic drugs to restore sinus rhythm and to reduce the frequency of recurrences of atrial fibrillation are the primary therapy. While this strategy has been shown to effectively reduce the frequency of symptomatic recurrences of atrial fibrillation, concerns about the safety of antiarrhythmic drugs have increased interest in alternative strategies including a simpler strategy of controlling the heart rate during atrial fibrillation (with beta blockers, digoxin, verapamil or diltiazem). Some patients are being treated with His bundle ablation and implantation of a permanent pacemaker, which eliminates the need for all drug therapy except for anticoagulation. At the present time, the effect on survival of these alternative strategies for management of patients with atrial fibrillation is simply unknown. The overall goal of the AFFIRM trial is to determine whether a strategy of maintaining sinus rhythm with class I or class III antiarrhythmic drugs is different from a strategy of simply controlling rate with respect to mortality. In the AFFIRM trial, patients are randomly assigned to one of these two competing strategies. Once that assignment has been made, investigators have wide latitude in deciding exactly which drugs or devices to use. The protocol will enroll 5,000 patients. The primary outcome variable is mortality. Almost half the patients have already been recruited.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA
  • 批准号:
    6565344
  • 项目类别:
  • 资助金额:
    $11.7万
  • 财政年份:
    2001
  • 负责人:
    EDWARD L PRITCHETT
  • 依托单位:
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)
  • 批准号:
    6565362
  • 项目类别:
  • 资助金额:
    $11.7万
  • 财政年份:
    2001
  • 负责人:
    EDWARD L PRITCHETT
  • 依托单位:
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS
  • 批准号:
    6565324
  • 项目类别:
  • 资助金额:
    $11.7万
  • 财政年份:
    2001
  • 负责人:
    EDWARD L PRITCHETT
  • 依托单位:
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA
  • 批准号:
    6463047
  • 项目类别:
  • 资助金额:
    $11.7万
  • 财政年份:
    2000
  • 负责人:
    EDWARD L PRITCHETT
  • 依托单位:
海外基金